Tilray Brands Past Earnings Performance
Past criteria checks 0/6
Tilray Brands's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 16.2% per year.
Key information
-36.9%
Earnings growth rate
-17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 16.2% |
| Return on equity | -5.8% |
| Net Margin | -26.2% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tilray Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 812 | -213 | 258 | 1 |
| 31 May 24 | 789 | -245 | 247 | 1 |
| 29 Feb 24 | 743 | -368 | 242 | 0 |
| 30 Nov 23 | 700 | -1,446 | 233 | 0 |
| 31 Aug 23 | 651 | -1,458 | 229 | 1 |
| 31 May 23 | 627 | -1,453 | 231 | 1 |
| 28 Feb 23 | 596 | -1,792 | 228 | 1 |
| 30 Nov 22 | 603 | -578 | 234 | 1 |
| 31 Aug 22 | 614 | -501 | 228 | 1 |
| 31 May 22 | 628 | -477 | 233 | 2 |
| 28 Feb 22 | 617 | 42 | 217 | 2 |
| 30 Nov 21 | 589 | -275 | 193 | 2 |
| 31 Aug 21 | 564 | -375 | 181 | 1 |
| 31 May 21 | 513 | -367 | 156 | 1 |
| 28 Feb 21 | 468 | -521 | 143 | 1 |
| 30 Nov 20 | 462 | -243 | 144 | 1 |
| 31 Aug 20 | 426 | -149 | 138 | 2 |
| 31 May 20 | 405 | -103 | 128 | 2 |
| 29 Feb 20 | 387 | 22 | 117 | 2 |
| 30 Nov 19 | 338 | -63 | 119 | 1 |
| 31 Aug 19 | 263 | -16 | 105 | 1 |
| 31 May 19 | 179 | -25 | 97 | 1 |
| 28 Feb 19 | 92 | -28 | 80 | 1 |
| 30 Nov 18 | 43 | 63 | 55 | 1 |
| 31 Aug 18 | 34 | 27 | 44 | 1 |
| 31 May 18 | 28 | 23 | 34 | 0 |
| 28 Feb 18 | 24 | 25 | 22 | 0 |
| 30 Nov 17 | 20 | 18 | 16 | 0 |
| 31 Aug 17 | 18 | 15 | 14 | 0 |
| 31 May 17 | 15 | 3 | 10 | 0 |
| 28 Feb 17 | 13 | 6 | 9 | 0 |
| 30 Nov 16 | 11 | 2 | 7 | 0 |
| 31 Aug 16 | 9 | 1 | 6 | 0 |
| 31 May 16 | 6 | 0 | 5 | 0 |
| 29 Feb 16 | 5 | -1 | 4 | 0 |
| 30 Nov 15 | 3 | -3 | 3 | 0 |
| 31 Aug 15 | 1 | -4 | 3 | 0 |
| 31 May 15 | 0 | -5 | 3 | 0 |
| 28 Feb 15 | 0 | -5 | 3 | 0 |
| 30 Nov 14 | 0 | -3 | 3 | 0 |
| 31 Aug 14 | 0 | -3 | 2 | 0 |
Quality Earnings: 2HQ is currently unprofitable.
Growing Profit Margin: 2HQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2HQ is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.
Accelerating Growth: Unable to compare 2HQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2HQ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 2HQ has a negative Return on Equity (-5.78%), as it is currently unprofitable.